Synopsis: Oxaliplatin, which belongs to platinum derivatives and is clinically used to treat patients with colorectal cancer metastases after failure of fluorouracil treatment, either alone or in combination with fluorouracil, is the third-generation novel platinum based antitumor compound after cisplatin, carboplatin and the only complex platinum based drug with significant activity against colorectal cancer to date. The principle of action is to act on DNA by producing alkylated conjugates, forming intra - and interstrand crosslinks that inhibit DNA synthesis and replication. It also inhibited proliferation in ovarian cancer and melanoma cell lines.
Structural formula:
Properties
Summary
Oxaliplatin, which belongs to platinum derivatives and is clinically used to treat patients with colorectal cancer metastases after failure of fluorouracil treatment, either alone or in combination with fluorouracil, is the third-generation novel platinum based antitumor compound after cisplatin, carboplatin and the only complex platinum based drug with significant activity against colorectal cancer to date. The principle of action is to act on DNA by producing alkylated conjugates, forming intra - and interstrand crosslinks that inhibit DNA synthesis and replication. It also inhibited proliferation in ovarian cancer and melanoma cell lines.
Manufacturing
